WHAT IS CLAIMED:

1. A compound of formula (I):



Formula I

wherein:

the carbon atom designated * is in the R or S configuration;
or a pharmaceutically acceptable salt thereof or a solvate thereof.

2. The compound according to claim 1, wherein the compound is a (+)-stereoisomer.

3. The compound according to claim 1, wherein the compound is a (-)-stereoisomer.

4. The compound according to claim 1, wherein the compound is in the S configuration.

5. The compound according to claim 1, wherein the compound is in the R configuration.

6. The compound according to claim 1, wherein the compound is a (S)(+)-stereoisomer.

7. The compound according to claim 1, wherein the compound is a (R)(-)-stereoisomer.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound according to claim 1.

9. Use of therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder which is created by or is dependent upon decreased availability of norepinephrine, dopamine, or serotonin.

10. Use of a compound for the manufacture of a medicament according to claim 9, wherein the disorder is selected from the group consisting of attention deficit hyperactivity disorder (ADHD), cognition impairment, anxiety disorders, generalized anxiety disorder (GAD), panic disorder, bipolar disorder or manic depression or manic-depressive disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), major depressive disorder (MDD), postnatal depression, dysthymia, depression associated with Alzheimer's disease, Parkinson's disease, or psychosis, supranuclear palsy, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, diabetes, ischemic diseases, pain, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, amphetamine addiction, alcohol addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, Parkinson's disease, late luteal phase syndrome or narcolepsy, psychiatric symptoms, anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorders, restless leg syndrome (RLS), tardive dyskinesia, supranuclear palsy, sleep related eating disorder (SRED), night eating syndrome (NES), stress urinary incontinence (SUI), migraine, neuropathic pain, diabetic neuropathy, lower back pain, fibromyalgia syndrome (FS), osteoarthritis pain, arthritis pain, chronic fatigue syndrome (CFS), sexual dysfunction, premature ejaculation, male impotence, thermoregulatory disorders (e.g., hot flashes associated with menopause), and irritable bowel syndrome (IBS).

11. Use of a compound for the manufacture of a medicament according to claim 9 further comprising:

a therapeutically effective amount of a serotonin 1A receptor antagonist or a pharmaceutically acceptable salt thereof.

12. Use of a compound for the manufacture of a medicament according to claim 11, wherein the serotonin 1A receptor antagonist is selected from the group consisting of WAY 100135 and spiperone.

13. Use of a compound for the manufacture of a medicament according to claim 9 further comprising:

a therapeutically effective amount of a selective neurokinin-1 receptor antagonist or a pharmaceutically acceptable salt thereof.

14. Use of a compound for the manufacture of a medicament according to claim 9 further comprising:

a therapeutically effective amount of a norepinephrine precursor or a pharmaceutically acceptable salt thereof.

15. Use of a compound for the manufacture of a medicament according to claim 14, wherein the norepinephrine precursor is selected from the group consisting of L-tyrosine and L-phenylalanine.

16. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (+)-stereoisomer.

17. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (-)-stereoisomer.

18. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is in the S configuration.

19. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is in the R configuration.

20. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (S)(+)-stereoisomer.

21. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (R)(-)-stereoisomer.

22. Use of a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting synaptic norepinephrine uptake in a patient.

23. Use of a compound for the manufacture of a medicament according to claim 22, wherein the compound is a (+)-stereoisomer.

24. Use of a compound for the manufacture of a medicament according to claim 22, wherein the compound is a (-)-stereoisomer.

25. Use of a compound for the manufacture of a medicament according to claim 22, wherein the compound is a (S)(+)-stereoisomer.

26. Use of a compound for the manufacture of a medicament according to claim 22, wherein the compound is a (R)(-)-stereoisomer.

27. Use of a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting synaptic serotonin uptake in a patient.

28. Use of a compound for the manufacture of a medicament according to claim 27, wherein the compound is a (+)-stereoisomer.

29. Use of a compound for the manufacture of a medicament according to claim 27, wherein the compound is a (-)-stereoisomer.

30. Use of a compound for the manufacture of a medicament according to claim 27, wherein the compound is a (S)(+)-stereoisomer.

31. Use of a compound for the manufacture of a medicament according to claim 27, wherein the compound is a (R)(-)-stereoisomer.

32. Use of a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting synaptic dopamine uptake in a patient.

33. Use of a compound for the manufacture of a medicament according to claim 32, wherein the compound is a (+)-stereoisomer.

34. Use of a compound for the manufacture of a medicament according to claim 32, wherein the compound is a (-)-stereoisomer.

35. Use of a compound for the manufacture of a medicament according to claim 32, wherein the compound is a (S)(+)-stereoisomer.

36. Use of a compound for the manufacture of a medicament according to claim 32, wherein the compound is a (R)(-)-stereoisomer.

37. Use of an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for suppressing the desire of humans to smoke.

38. Use of a compound for the manufacture of a medicament according to claim 37, wherein the compound is a (+)-stereoisomer.

39. Use of a compound for the manufacture of a medicament according to claim 37, wherein the compound is a (-)-stereoisomer.

40. Use of a compound for the manufacture of a medicament according to claim 37, wherein the compound is a (S)(+)-stereoisomer.

41. Use of a compound for the manufacture of a medicament according to claim 37, wherein the compound is a (R)(-)-stereoisomer.

42. Use of an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for suppressing the desire of humans to consume alcohol.

43. Use of a compound for the manufacture of a medicament according to claim 42, wherein the compound is a (+)-stereoisomer.

44. Use of a compound for the manufacture of a medicament according to claim 42, wherein the compound is a (-)-stereoisomer.

45. Use of a compound for the manufacture of a medicament according to claim 42, wherein the compound is a (S)(+)-stereoisomer.

46. Use of a compound for the manufacture of a medicament according to claim 42, wherein the compound is a (R)(-)-stereoisomer.

WHAT IS CLAIMED:

1. A compound of formula (I):



Formula I

wherein:

the carbon atom designated * is in the R or S configuration;
or a pharmaceutically acceptable salt thereof or a solvate thereof.

2. The compound according to claim 1, wherein the compound is a (+)-stereoisomer.

3. The compound according to claim 1, wherein the compound is a (-)-stereoisomer.

4. The compound according to claim 1, wherein the compound is in the S configuration.

5. The compound according to claim 1, wherein the compound is in the R configuration.

6. The compound according to claim 1, wherein the compound is a (S)(+)-stereoisomer.

7. The compound according to claim 1, wherein the compound is a (R)(-)-stereoisomer.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound according to claim 1.

9. Use of therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder selected from the group consisting attention deficit hyperactivity disorder (ADHD), cognition impairment, anxiety disorders, generalized anxiety disorder (GAD), panic disorder, bipolar disorder or manic depression or manic-depressive disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), major depressive disorder (MDD), postnatal depression, dysthymia, depression associated with Alzheimer's disease, Parkinson's disease, or psychosis, supranuclear palsy, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, diabetes, ischemic diseases, pain, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, amphetamine addiction, alcohol addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, Parkinson's disease, late luteal phase syndrome or narcolepsy, psychiatric symptoms, anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorders, restless leg syndrome (RLS), tardive dyskinesia, supranuclear palsy, sleep related eating disorder (SRED), night eating syndrome (NES), stress urinary incontinence (SUI), migraine, neuropathic pain, diabetic neuropathy, lower back pain, fibromyalgia syndrome (FS), osteoarthritis pain, arthritis pain, chronic fatigue syndrome (CFS), sexual dysfunction, premature ejaculation, male impotence, thermoregulatory disorders (e.g., hot flashes associated with menopause), and irritable bowel syndrome (IBS).

10. Use of a compound for the manufacture of a medicament according to claim 9 further comprising:

a therapeutically effective amount of a serotonin 1A receptor antagonist or a pharmaceutically acceptable salt thereof.

11. Use of a compound for the manufacture of a medicament according to claim 10, wherein the serotonin 1A receptor antagonist is selected from the group consisting of WAY 100135 and spiperone.

12. Use of a compound for the manufacture of a medicament according to claim 9 further comprising:

a therapeutically effective amount of a selective neurokinin-1 receptor antagonist or a pharmaceutically acceptable salt thereof.

13. Use of a compound for the manufacture of a medicament according to claim 9 further comprising:

a therapeutically effective amount of a norepinephrine precursor or a pharmaceutically acceptable salt thereof.

14. Use of a compound for the manufacture of a medicament according to claim 13, wherein the norepinephrine precursor is selected from the group consisting of L-tyrosine and L-phenylalanine.

15. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (+)-stereoisomer.

16. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (-)-stereoisomer.

17. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is in the S configuration.

18. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is in the R configuration.

19. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (S)(+)-stereoisomer.

20. Use of a compound for the manufacture of a medicament according to claim 9, wherein the compound is a (R)(-)-stereoisomer.